1. Home
  2. Conferences
  3. TSCA Developments 2020
  4. programme

Programme

**Note: timings are in EDT**

  1. Welcome and introduction

    Moderator:

    Terry Hyland Terry Hyland
    Senior Editor, North America, Chemical Watch News & Insight, by Enhesa, USA
  2. Session one: Regulatory updates

  3. Keynote  Keynote: TSCA Updates from the EPA

    Alexandra Dapolito Dunn Alexandra Dapolito Dunn
    Partner, Baker Botts

  4. TSCA chemical data reporting (CDR) 2020: Something old, something new

    • Update on the current reporting window
    • Update on the small business definition
    Jeff Hafer Jeff Hafer
    Senior Regulatory Scientist, knoell USA, United States

  5. TSCA fees

    • Upcoming rulemaking on fee exemptions
    • Overview of self-identification process
    • Strategies for payment: How are consortia dividing up fees between participants?
    Lynn L. Bergeson Lynn L. Bergeson
    Managing Partner, Bergeson & Campbell, USA

  6. Q&A

  7. TSCA new chemical programme

    • Changes under the LCSA
    • Their Impact on the Chemical Industry
    • Practical Considerations and Recommendations
    John J. Kowalski John J. Kowalski
    Regulatory Affairs Lead, UL Solutions, USA

  8. TSCA new chemical programme statistics and pre-manufacture notice (PMN) status

    • Programme statistics: update on PMN 'backlog' and EPA new chemical review efforts
    • A reflection on PMN submissions since the new higher fees took effect
    Devin Millions Devin Millions
    Managing Scientist, Exponent

  9. Q&A

  10. Chemical Watch platform and service demonstration

    Tassia Agatowski Tassia Agatowski
    Marketing Manager, Chemical Watch

  11. Break

  12. Session two: Risk management and evaluation

  13. A reflection on recent risk evaluations: NGO perspective

    Is the EPA risk evaluation process effectively protecting the public?

    • The impact of the SACC peer review process
    • Gaps in the EPA evaluations
    • Important policy and legal issues
    Bob Sussman Bob Sussman
    Counsel, Safer Chemicals Healthy Families, and Principal, Sussman and Associates, United States

  14. Preview of emerging issues on the next 20 risk evaluations: Lessons learned from the first 10

    • Should we expect the EPA to issue test orders and make other efforts to fill data gaps? 
    • What role are industry consortia playing in this process?
    Herb Estreicher Herb Estreicher
    Partner, Keller and Heckman, United States

  15. Q&A

  16. Session three: Confidential business information (CBI) under TSCA, enforcement and litigation

  17. CBI substantiation overview

    • Issues that could cause the EPA to drop a chemical identity confidentiality claim and what recourse companies have to stop this
    • An insight into CBI’s upfront substantiation requirements
    Erik Baptist Erik Baptist
    Partner, Wiley Rein LLP

  18. Enforcement and litigation issues including enforcement during the Covid-19 pandemic

    Sara Beth Watson Sara Beth Watson
    Counsel, Steptoe and Johnson LLP

  19. Q&A

  20. Break

  21. Session four: Stakeholder perspectives and outlooks

  22. Covid 19 – the impact of the coronavirus on TSCA

  23. Reflections on four years of implementing the Lautenberg Amendments: a former EPA insider’s perspective and advice

    Erik Baptist Erik Baptist
    Partner, Wiley Rein LLP

  24. Stakeholder panel: A look to the future

    Richard Engler, Ph.D. Richard Engler, Ph.D.
    Director of Chemistry, Bergeson & Campbell, P.C.
    Jeff Hafer Jeff Hafer
    Senior Regulatory Scientist, knoell USA, United States
    Erik Baptist Erik Baptist
    Partner, Wiley Rein LLP

  25. Q&A and conference wrap-up

    Chemical Watch

Back to top